900
Participants
Start Date
January 31, 2001
Primary Completion Date
January 31, 2005
Study Completion Date
January 31, 2005
stavudine, efavirenz, lamivudine
Local Institution, Berkeley
Local Institution, Los Angeles
Local Institution, West Hollywood
Local Institution, Washington D.C.
Local Institution, Fort Lauderdale
Local Institution, Orlando
Local Institution, Tampa
Local Institution, Indianapolis
Local Institution, Wichita
Local Institution, Louisville
Local Institution, Brookline
Local Institution, Las Vegas
Local Institution, Reno
Local Institution, New York
Local Institution, Winston-Salem
Local Institution, Oklahoma City
Local Institution, Dallas
Local Institution, Houston
Local Institution, Hampton
Local Institution, San Isidro
Local Institution, Rosario
Local Institution, Buenos Aires
Local Institution, Córdoba
Local Institution, Ghent
Local Institution, Liège
Local Institution, Salvador
Local Institution, Belo Horizonte - MG
Local Institution, Botucatu
Local Institution, Santos
Local Institution, Vancouver
Local Institution, Toronto
Local Institution, Montreal
Local Institution, Bordeaux
Local Institution, Lyon
Local Institution, Nantes
Local Institution, Paris
Local Institution, Rennes
Local Institution, Rehovot
Local Institution, Tel Hashorner
Local Institution, Bari
Local Institution, Bergamo
Local Institution, Florence
Local Institution, Milan
Local Institution, Napoli
Local Institution, Pisa
Local Institution, Torino
Local Institution, Mexico City
Local Institution, Coimbra
Local Institution, Lisbon
Local Institution, Cotto Laurel
Local Institution, San Juan
Local Institution, Moscow
Local Institution, Saint Petersburg
Local Institution, Singapore
Local Institution, Bedford Gardens
Local Institution, Hatfield
Local Institution, Johannesburg
Local Institution, Westdene
Local Institution, Tygerberg
Local Institution, Barcelona
Local Institution, Madrid
Local Institution, Bangkok
Local Institution, Nontaburi
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY